<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334617</url>
  </required_header>
  <id_info>
    <org_study_id>D6185C00001</org_study_id>
    <secondary_id>2017-002208-28</secondary_id>
    <secondary_id>138050</secondary_id>
    <nct_id>NCT03334617</nct_id>
  </id_info>
  <brief_title>Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy</brief_title>
  <acronym>HUDSON</acronym>
  <official_title>An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
      NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in
      design, allowing initial assessment of the efficacy, safety, and tolerability of multiple
      treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
      non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell
      death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study
      is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the
      efficacy, safety, and tolerability of multiple treatment arms. There is currently no
      established therapy for patients who have received immune checkpoint inhibitors and
      platinum-doublet therapies, and novel treatments are urgently needed.

      This protocol has a modular design, with the potential for future treatment arms to be added
      via protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">December 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Within each module, there will be treatment cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the efficacy of each treatment by evaluation of objective response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Endpoint based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Objective response rate (ORR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) using RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percentage change in tumour size using RECIST 1.1 assessment for the anti-tumour activity of each therapy</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) using RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) using RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall surival (OS)</measure>
    <time_frame>Through to study completion, up to 4.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events/serious adverse events to assess the safety and tolerability of each treatment</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Physical examinations, laboratory findings, and vital signs AEs/SAEs collected throughout the study, from informed consent until the safety follow-up visit</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with olaparib .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with AZD9150.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with AZD6738.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with Vistusertib (AZD2014).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + Oleclumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with Oleclumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>durvalumab + trastuzumab deruxtecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>durvalumab + cediranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab given in combination with cediranib (AZD2171)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab given IV at 1500 mg Q4W Â±2 days</description>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
    <arm_group_label>Durvalumab + Oleclumab</arm_group_label>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
    <arm_group_label>durvalumab + cediranib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9150</intervention_name>
    <description>AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW</description>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6738</intervention_name>
    <description>AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28</description>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vistusertib</intervention_name>
    <description>Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off</description>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib (AZD2281) given orally at 300 mg BD</description>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleclumab</intervention_name>
    <description>Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter</description>
    <arm_group_label>Durvalumab + Oleclumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab deruxtecan</intervention_name>
    <description>Durvalumab given IV at 1120mg Q3W Â±2 days for Module 6 only &amp; trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W Â±2 days</description>
    <arm_group_label>durvalumab + trastuzumab deruxtecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib</intervention_name>
    <description>cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1</description>
    <arm_group_label>durvalumab + cediranib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  At least 18 years of age at the time of signing the informed consent form.

          -  Patient must have histologically or cytologically confirmed metastatic or locally
             advanced and recurrent NSCLC which is progressing.

          -  Patients eligible for second- or later-line therapy, who must have received an
             antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced
             or metastatic NSCLC either separately or in combination. Prior durvalumab is
             acceptable. The patient must have had disease progression on a prior line of
             antiPD1/PD-L1 therapy.

          -  ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

          -  Patient must have at least 1 lesion that can be accurately measured. A previously
             irradiated lesion can be considered a target lesion if the lesion has clearly
             progressed.

          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre-menopausal patients.

        Exclusion Criteria:

          -  Patients whose tumour samples have targetable alterations in EGFR and/or ALK are
             excluded. In addition, patients whose tumour samples are known to have targetable
             alterations in ROS1, BRAF, MET or RET, are to be excluded.

          -  Active or prior documented autoimmune or inflammatory disorders.

          -  Active infection including tuberculosis, hepatitis B (known positive HBV surface
             antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV
             1/2 antibodies).

          -  Female patients who are pregnant or breastfeeding, or male or female patients of
             reproductive potential who are not willing to employ effective birth control.

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients.

          -  Patient has spinal cord compression or symptomatic brain metastases.

          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
             treatment. Patients may receive treatment with bisphosphonates or receptor activator
             of nuclear factor kappa-Î ligand (RANKL) inhibitors for the treatment of bone
             metastases.

          -  history of active primary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Heymach, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas MD Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cancer Study Locator</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L2P 2V3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>20927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>95847</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>anti-PD-1/PD-L1</keyword>
  <keyword>umbrella study</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Olaparib</keyword>
  <keyword>AZD2281</keyword>
  <keyword>AZD9150</keyword>
  <keyword>AZD6738</keyword>
  <keyword>Vistusertib</keyword>
  <keyword>AZD2014</keyword>
  <keyword>Oleclumab</keyword>
  <keyword>MEDI9447</keyword>
  <keyword>Trastuzumab deruxtecan</keyword>
  <keyword>DS-8201a</keyword>
  <keyword>cediranib</keyword>
  <keyword>AZD2171</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

